Summary
Residual beta cell secretory capacity was assessed in short term (2 months to 2 years) and long term (5 to 8 years) insulin-dependent diabetics by measurement of serum C-peptide immunoreactivity during three provocative tests: glucose, tolbutamide, and glucagon. Minimal C-peptide secretion could be detected in only one out of seven long term diabetics by the stimulatory tests. All seven short-term diabetics responded to at least one provocative test of beta cell reserve, although these responses were blunted. The greatest C-peptide responses occurred after glucagon administration (mean increase 0.62 pmol/ml) in short-term responders. Patients who responded to one test did not necessarily respond to another stimulus. There was no correlation between basal C-peptide levels and the ability to provoke further C-peptide secretion by any of the three tests. C-peptide responses did not correlate with % Haemoglobin A1c, mean fasting blood glucose levels, or mean blood glucose concentrations during an oral glucose tolerance test. The data indicate that stimulation tests are only useful in assessing endogenous beta cell reserve in patients with diabetes of less than 5 years duration. In diabetics of longer duration there is little insulin reserve above basal levels.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Block MB, Mako ME, Steiner DF, Rubenstein AH (1972) Circulating C-peptide immunoreactivity: studies in normals and diabetic patients. Diabetes 21: 1013–1026
Block MB, Rosenfield RL, Mako ME, Steiner DF, Rubenstein AH (1973) Sequential changes in beta cell function in insulin-treated diabetic patients assessed by C-peptide immunoreacitivity. N Engl J M 288: 1144–1148
Cahill GF Jr (1973) C-peptide: a new method of assessing pancreatic beta cell function (editorial). N Engl J Med 288: 1181–1182
Heding LG, Rasmussen SM (1975) Human C-peptide in normal and diabetic subjects. Diabetologia 11: 201–206
Horwitz DL, Kuzuya H, Rubenstein AH (1976) Circulating serum C-peptide: a brief review of diagnostic implications. N Engl J Med 295: 207–209
Horwitz DL, Rubenstein AH, Katz AI (1977) Quantitation of human pancreatic beta-cell function by immunoassay of Cpeptide in urine. Diabetes 26: 30–35
Kitabchi AE (1977) Proinsulin and C-peptide: a review. Metabolism 26: 547–587
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Beischer W, Keller L, Maas M, Schiefer E, Pfeiffer EF (1976) Human C-peptide. Part I: radioimmunoassay. Klin Wochenschr 54: 709–715
Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH (1977) Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 26: 22–29
Kuzuya T, Matsuda A, Saito T, Yoshida S (1976) Human Cpeptide immunoreacitivity (CPR) in blood and urine-evaluation of radioimmunoassay method and its clinical applications. Diabetologia 12: 511–518
Beischer W, Heinze E, Keller L, Raptis S, Kerner W, Pfeiffer EF (1976) Human C-peptide. Part III: clinical studies. Klin Wochenschr 54: 717–725
Ludvigsson J, Heding LG (1977) C-peptide in diabetic children after stimulation with glucagon compared with fasting C-peptide levels in non-diabetic children. Acta Endocrinol (Kbh) 85: 364–371
Unger RH, Aguilar-Parada E, Müller WA, Eisenstraut AM (1970) Studies of pancreatic alpha-cell function in normal and diabetic subjects. J Clin Invest 49: 837–848
Trivelli LS, Ranney HM, Lai H-T (1971) Hemoglobin components in patients with diabetes mellitus. N Engl J Med 284: 353–357
Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A (1976) Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med 295: 417–420
Ginsberg-Felmer F, Dobersen M, Witt M, Notkins A, Rubinstein P, Rayfield EJ (1979) HLA antigens, islet cell antibodies and carbohydrate metabolism in siblings of children with insulin-dependent diabetes mellitus (Abstract). Diabetes [Suppl] 28: 396
Bucolo G, David H (1973) Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 19: 476–482
Faber OK, Binder C, Markassen J, Heding LG, Naithani VK, Kuzuya H, Blix P, Horwitz DL, Rubenstein AH (1978) Characterization of seven C-peptide antisera. Diabetes [Suppl] 27: 170–177
Snedecor GW, Cochran WG (1967) Statistical methods, 6th ed, 91. The Iowa State Univ Press, Ames, Iowa
Melani F, Rubenstein AH, Steiner DF (1970) Human serum proinsulin. J Clin Invest 49: 497–507
Grajwer LA, Pildes RS, Horwitz DL, Rubenstein AH (1977) Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. J Pediatr 90: 42–48
Yue DK, Baxter RC, Turtle JR (1978) C-peptide secretion and insulin antibodies as determinants of stability in diabetes mellitus. Metabolism 27: 35–44
Faber OK, Binder C (1977) C-peptide response to glucagon: a test for the residual B-cell function in diabetes mellitus. Diabetes 26: 605–610
Unger RH, Aydin I, Nakabayashi H, Srikant CB, Raskin P (1976) The effects of glucagon administration to non-diabetics and diabetics. Metabolism [Suppl 1] 25: 1523–1526
Binder C, Faber OK (1978) Residual beta-cell function and its metabolic consequences. Diabetes [Suppl] 27: 226–229
Heding LG (1978) Insulin, C-peptide, and Proinsulin in nondiabetics and insulin-treated diabetics. Diabetes [Suppl 1] 27: 178–183
Horwitz DL. Starr JI, Mako ME, Blackard WG, Rubenstein AH (1975) Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 55: 1278–1283
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mirel, R.D., Ginsberg-Fellner, F., Horwitz, D.L. et al. C-peptide reserve in insulin-dependent diabetes. Diabetologia 19, 183–188 (1980). https://doi.org/10.1007/BF00275266
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00275266